ClinicalTrials.gg
CompletedNCT02693613Updated Jun 21, 2016

Pharmacokinetic Study of ASP1517 With Kremezin®

A Phase 1 interventional study of ASP1517 and Kremezin® in Healthy Volunteers, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to male participants aged 20 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-21.

Sponsored by Astellas Pharma Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
20 Years to 44 Years
Sex
Male
01

Study summary

The objective of this study is to evaluate the effect of Kremezin® on the pharmacokinetics of single dose of ASP1517 in healthy non-elderly adult male subjects when administered concomitantly or in a time separated manner.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Drug-drug interaction
  • Kremezin
  • Pharmacokinetics
  • ASP1517
03

In context

Lead sponsor

Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 44 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight (at screening): ≥50.0 kg and \<80.0 kg
  • Body-mass index () (at screening): ≥17.6 and \<26.4 kg/m2
  • Subject must agree to use consisting of two established forms (1 of which must be a barrier method) starting at the time of and continuing throughout the treatment period and for 84days after ASP1517 administration in the last period:
  • Subject must agree not to donate sperm starting at the time of informed consent and continuing throughout 84 days after the last administration of ASP1517 in the last period.

Exclusion criteria

Exclusion Criteria:

  • Received or is scheduled to receive any drugs in other clinical trials or post-marketing studies within 120 days before screening or during the period from screening to the hospital admission day of the Period 1 (Day -1).
  • Received or is scheduled to receive medications (including over-the-counter [OTC] drugs) within 7 days before the hospital admission day of the Period 1 (Day -1).
  • Received or is scheduled to receive supplements within 7 days before the hospital admission day of the Period 1 (Day -1).
  • Deviates from any of the normal range of blood pressure, pulse rate, body temperature and standard 12-lead (ECG) specified at screening or the hospital admission day of the Period 1 (Day -1).
  • Meets any of the following criteria for laboratory tests at screening or the hospital admission day of the Period 1 (Day -1). Normal ranges of each test specified at the study site or the test/assay organization will be used as the normal ranges in this study.
  • Concurrent or previous drug allergies.
  • Development of (an) upper gastrointestinal symptoms within seven days before the hospital admission day of the Period 1 (Day -1).
  • Concurrent or previous hepatic disease, heart disease, respiratory disease, gastrointestinal disease, gastrointestinal obstruction,oesophageal varices, renal disease, endocrine disease, cerebrovascular disorder, malignant tumor, retinal neovascular lesions and macular edema.
  • Concurrent chronic constipation or diarrhoea.
  • A history of digestive tract excision.
  • Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such as ASP1517 (FG-4592), YM311 (FG-2216) or erythropoietin products.
  • Excessive alcohol or smoking habit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group 1

    Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)

    Drug: ASP1517 · Drug: Kremezin®

  • Experimental
    Group 2

    Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)

    Drug: ASP1517 · Drug: Kremezin®

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) parameter of ASP1517: AUCinf

    AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  2. PK parameter of ASP1517: Cmax

    Cmax: Maximum concentration

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

Secondary outcomes

  1. PK parameters of ASP1517: AUClast

    AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  2. PK parameters of ASP1517: CL/F

    CL/F: Apparent total systemic clearance

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  3. PK parameters of ASP1517: t1/2

    t1/2: Terminal elimination half-life

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  4. PK parameters of ASP1517: tmax

    tmax: Time of Cmax

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  5. PK parameters of ASP1517: tlag

    tlag: Time point prior to the time point corresponding to the first measurable (non-zero) concentration

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  6. PK parameters of ASP1517: Vz/F

    Vz/F: Apparent volume of distribution during the terminal elimination phase

    Time frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing

  7. Safety assessed by Adverse events

    Time frame: Up to 72 hours after final study drug dosing

  8. Safety assessed by Vital signs

    Supine blood pressure, supine pulse rate and axillary body temperature

    Time frame: Up to 72 hours after each study drug dosing

  9. Safety assessed by Laboratory tests

    Hematology, blood biochemistry and urinalysis

    Time frame: Up to 72 hours after each study drug dosing

  10. Safety assessed by Standard 12-lead ECG

    ECG: Electrocardiogram

    Time frame: Up to 72 hours after each study drug dosing

07

Study locations

1 site
  • Site JP00001
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 29, 2016
Start
Feb 2016
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Last update
Jun 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02693613
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Feb 2016
Primary completion
Apr 2016
Completion
Apr 2016
Last update
Jun 21, 2016

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roxadustat · AST 120 · Charcoal

Start the discussion